Please assess the completion status of the following clinical trial:

Trial Title: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent form.~* Age ≥18 years at the time of signing the informed consent form.~* Diagnosis of any monoclonal gammopathy: Monoclonal Gammopathy of Undetermined Significance (MGUS), asymptomatic / active multiple myeloma, asymptomatic / active Waldenstrӧm Macroglobulinemia (WM).~Exclusion Criteria:~* Any serious egg allergy or prior serious adverse reaction to an influenza vaccine.~* Use of any other influenza vaccine for the 2015 to 2016 flu season.~* Women who are pregnant or plan to become pregnant in the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Fluzone High Dose Vaccine then Fluzone High Dose Booster (Type: EXPERIMENTAL): Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
- Standard of Care (Type: ACTIVE_COMPARATOR): Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).